Why the study?
Does triple combination immunosuppressive therapy with prednisolone, cyclosporine, and mycophenolate mofetil improve outcomes in recurrent giant cell myocarditis?
Does triple combination immunosuppressive therapy with prednisolone, cyclosporine, and mycophenolate mofetil improve outcomes in recurrent giant cell myocarditis?
Triple combination immunosuppressive therapy with prednisolone, cyclosporine, and mycophenolate mofetil successfully treated recurrent giant cell myocarditis and facilitated left ventricular functional recovery.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for triple immunosuppression in recurrent giant cell myocarditis; controlled trials needed before practice change.
A 59-year-old man with a history of giant cell myocarditis was admitted to our hospital with recurrent giant cell myocarditis triggered by a 1 mg/day taper in his prednisolone dose. During the initial episode, he had undergone rescue implantation of a temporary left ventricular assist device followed by the administration of dual immunosuppressive therapy with prednisolone and concomitant cyclosporine. Triple combination immunosuppressive therapy maintained with additional mycophenolate mofetil successfully controlled recurrent myocarditis, enabled a reduction in the prednisolone dose, and achieved the functional recovery of the left ventricle.
No takes yet. Share an insight, caveat, or question.
Akita et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: